Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

[Application of perioperative imatinib mesylate therapy in initial resectable primary local advanced gastrointestinal stromal tumor at intermediate or high risk].

Li SX, Li ZY, Zhang LH, Bu ZD, Wu AW, Wu XJ, Zong XL, Shan F, Ji X, Ji JF.

Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Mar;16(3):226-9. Chinese.

PMID:
23536340
2.

[Clinical analysis of 156 patients with gastrointestinal stromal tumors receiving imatinib therapy].

Zhang L, Cai M, Deng J, Wang X, Wang B, Liu N, Pan Y, Zhang R, Cui Q, Liang H.

Zhonghua Wei Chang Wai Ke Za Zhi. 2014 Apr;17(4):331-4. Chinese.

PMID:
24760639
3.

Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.

Rutkowski P, Gronchi A, Hohenberger P, Bonvalot S, Schöffski P, Bauer S, Fumagalli E, Nyckowski P, Nguyen BP, Kerst JM, Fiore M, Bylina E, Hoiczyk M, Cats A, Casali PG, Le Cesne A, Treckmann J, Stoeckle E, de Wilt JH, Sleijfer S, Tielen R, van der Graaf W, Verhoef C, van Coevorden F.

Ann Surg Oncol. 2013 Sep;20(9):2937-43. doi: 10.1245/s10434-013-3013-7. Epub 2013 Jun 13.

PMID:
23760587
4.
5.

Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.

Du CY, Zhou Y, Song C, Wang YP, Jie ZG, He YL, Liang XB, Cao H, Yan ZS, Shi YQ.

Eur J Cancer. 2014 Jul;50(10):1772-8. doi: 10.1016/j.ejca.2014.03.280. Epub 2014 Apr 22.

PMID:
24768330
6.

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial.

Blesius A, Cassier PA, Bertucci F, Fayette J, Ray-Coquard I, Bui B, Adenis A, Rios M, Cupissol D, Pérol D, Blay JY, Le Cesne A.

BMC Cancer. 2011 Feb 15;11:72. doi: 10.1186/1471-2407-11-72.

7.

Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.

DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, von Mehren M, McCarter MD, Norton J, Maki RG, Pisters PW, Demetri GD, Brennan MF, Owzar K; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology..

Ann Surg. 2013 Sep;258(3):422-9. doi: 10.1097/SLA.0b013e3182a15eb7.

8.

Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.

Jakob J, Mussi C, Ronellenfitsch U, Wardelmann E, Negri T, Gronchi A, Hohenberger P.

Ann Surg Oncol. 2013 Feb;20(2):586-92. doi: 10.1245/s10434-012-2647-1. Epub 2012 Sep 11.

PMID:
22965573
9.

Preoperative imatinib facilitates complete resection of locally advanced primary GIST by a less invasive procedure.

Yang W, Yu J, Gao Y, Shen Q, Zhang Q, Liu X, Zhao Z, Shi X, Zhu K, Ma Y.

Med Oncol. 2014 Sep;31(9):133. doi: 10.1007/s12032-014-0133-2. Epub 2014 Jul 24.

PMID:
25056206
10.

[Treatment progress of gastrointestinal stromal tumor].

Ji X, Ji JF.

Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Mar;16(3):292-6. Review. Chinese.

PMID:
23536354
11.

Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor.

Shen C, Chen H, Yin Y, Chen J, Zhang B, Chen Z, Chen J.

Clinics (Sao Paulo). 2014 Nov;69(11):758-62. doi: 10.6061/clinics/2014(11)09.

12.

Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study).

Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, Nguyen BP, Kerst M, Fiore M, Nyckowski P, Hoiczyk M, Cats A, Casali PG, Treckmann J, van Coevorden F, Gronchi A.

Eur J Surg Oncol. 2014 Apr;40(4):412-9. doi: 10.1016/j.ejso.2013.12.020. Epub 2014 Jan 15.

PMID:
24491288
13.

Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.

Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M, Eisenberg BL.

Ann Surg Oncol. 2012 Apr;19(4):1074-80. doi: 10.1245/s10434-011-2190-5. Epub 2011 Dec 28. Erratum in: Ann Surg Oncol. 2012 Jul;19(7):2420.

14.

Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome.

Zhao WY, Xu J, Wang M, Zhang ZZ, Tu L, Wang CJ, Cao H, Zhang ZG.

BMC Gastroenterol. 2014 Jun 7;14:105. doi: 10.1186/1471-230X-14-105.

15.

Clinical significance of pathological complete response in patients with metastatic gastrointestinal stromal tumors after imatinib mesylate treatment--lessons learned.

Cheng CT, Tsai CY, Yeh CN, Chiang KC, Chen YY, Wang SY, Chen TW, Tseng JH, Jung SM, Chen TC, Yeh TS.

Anticancer Res. 2014 Nov;34(11):6617-25.

PMID:
25368266
16.

Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.

Majer IM, Gelderblom H, van den Hout WB, Gray E, Verheggen BG.

J Med Econ. 2013 Sep;16(9):1106-19. doi: 10.3111/13696998.2013.819357. Epub 2013 Jul 19.

PMID:
23808902
17.

Gastrointestinal stromal tumor: 15-years' experience in a single center.

Wang M, Xu J, Zhang Y, Tu L, Qiu WQ, Wang CJ, Shen YY, Liu Q, Cao H.

BMC Surg. 2014 Nov 18;14:93. doi: 10.1186/1471-2482-14-93.

18.

[New prospective on adjuvant treatment for gastrointestinal stromal tumors].

Pan ZZ, Wu XJ.

Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Mar;16(3):212-5. Chinese.

PMID:
23536337
19.

[A case of a giant rectal gastrointestinal stromal tumor radically resectable after treatment with neoadjuvant imatinib mesylate].

Sassa M, Kobayashi Y, Sugeno H, Iwadate M, Suzuki S, Endo Y, Nakamura I, Ohki S, Takenoshita S.

Gan To Kagaku Ryoho. 2013 Jul;40(7):937-41. Review. Japanese.

PMID:
23863741
20.

Prognostic factors for primary gastrointestinal stromal tumours: are they the same in the multidisciplinary treatment era?

Cananzi FC, Lorenzi B, Belgaumkar A, Benson C, Judson I, Mudan S.

Langenbecks Arch Surg. 2014 Mar;399(3):323-32. doi: 10.1007/s00423-014-1160-3. Epub 2014 Jan 12.

PMID:
24413830

Supplemental Content

Support Center